144 related articles for article (PubMed ID: 2390837)
1. Discriminant factors affecting early outcome of radioiodine treatment for Graves' disease.
Kung AW; Choi P; Lam KS; Pun KK; Wang C; Yeung RT
Clin Radiol; 1990 Jul; 42(1):52-4. PubMed ID: 2390837
[TBL] [Abstract][Full Text] [Related]
2. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease.
Uy HL; Reasner CA; Samuels MH
Am J Med; 1995 Aug; 99(2):173-9. PubMed ID: 7625422
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine therapy for Graves' disease: multivariate analysis of pretreatment parameters and early outcome.
Turner J; Sadler W; Brownlie B; Rogers T
Eur J Nucl Med; 1985; 11(6-7):191-3. PubMed ID: 3841065
[TBL] [Abstract][Full Text] [Related]
4. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
[TBL] [Abstract][Full Text] [Related]
5. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
[TBL] [Abstract][Full Text] [Related]
6. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome.
Catargi B; Leprat F; Guyot M; Valli N; Ducassou D; Tabarin A
Eur J Endocrinol; 1999 Aug; 141(2):117-21. PubMed ID: 10427153
[TBL] [Abstract][Full Text] [Related]
7. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
[TBL] [Abstract][Full Text] [Related]
9. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
10. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
El Refaei SM; Shawkat W
Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
[TBL] [Abstract][Full Text] [Related]
11. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
[TBL] [Abstract][Full Text] [Related]
12. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease.
Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Hansen BM; Søe-Jensen P; Hansen JM
J Intern Med; 1995 Dec; 238(6):491-7. PubMed ID: 9422034
[TBL] [Abstract][Full Text] [Related]
13. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
[TBL] [Abstract][Full Text] [Related]
15. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].
Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T
Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826
[TBL] [Abstract][Full Text] [Related]
16. Correlation of radioiodine doses for 6-hr and 24-hour iodine-131 thyroid uptake values for Graves' hyperthyroidism.
Horn-Lodewyk J
Endocr J; 2019 Dec; 66(12):1047-1052. PubMed ID: 31391354
[TBL] [Abstract][Full Text] [Related]
17. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease.
Van Isselt JW; de Klerk JM; Koppeschaar HP; Van Rijk PP
Nucl Med Commun; 2000 Jul; 21(7):609-16. PubMed ID: 10994662
[TBL] [Abstract][Full Text] [Related]
18. Outcome following standardized 185 MBq dose 131I therapy for Graves' disease.
Watson AB; Brownlie BE; Frampton CM; Turner JG; Rogers TG
Clin Endocrinol (Oxf); 1988 May; 28(5):487-96. PubMed ID: 3214941
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up studies on iodine-131 treatment of hyperthyroid Graves' disease based on the measurement of thyroid volume by ultrasonography.
Tsuruta M; Nagayama Y; Yokoyama N; Izumi M; Nagataki S
Ann Nucl Med; 1993 Aug; 7(3):193-7. PubMed ID: 8217496
[TBL] [Abstract][Full Text] [Related]
20. Radioactive iodine in the treatment of Graves' disease.
Al-Kaabi JM; Hussein SS; Bukheit CS; Woodhouse NJ; Elshafie OT; Bererhi H
Saudi Med J; 2002 Sep; 23(9):1049-53. PubMed ID: 12370710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
